CD274 and non-small cell lung carcinoma: PD-L1 expression, microsatellite instability high (MSI-H)/mismatch repair deficiency (dMMR) and TMB have gained regulatory approval as predictive biomarkers for ICIs in the treatment of NSCLC (5, 8, 11–13).